ATE344043T1 - Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung - Google Patents

Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung

Info

Publication number
ATE344043T1
ATE344043T1 AT99943916T AT99943916T ATE344043T1 AT E344043 T1 ATE344043 T1 AT E344043T1 AT 99943916 T AT99943916 T AT 99943916T AT 99943916 T AT99943916 T AT 99943916T AT E344043 T1 ATE344043 T1 AT E344043T1
Authority
AT
Austria
Prior art keywords
alpha
hypoxia
inducible factor
mutein
stable
Prior art date
Application number
AT99943916T
Other languages
English (en)
Inventor
Gregg L Semenza
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE344043T1 publication Critical patent/ATE344043T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99943916T 1998-08-25 1999-08-25 Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung ATE344043T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/148,547 US6124131A (en) 1998-08-25 1998-08-25 Mutant hypoxia inducible factor-1 HIF-1

Publications (1)

Publication Number Publication Date
ATE344043T1 true ATE344043T1 (de) 2006-11-15

Family

ID=22526230

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99943916T ATE344043T1 (de) 1998-08-25 1999-08-25 Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung

Country Status (11)

Country Link
US (3) US6124131A (de)
EP (1) EP1107768B1 (de)
JP (1) JP2002523028A (de)
AT (1) ATE344043T1 (de)
AU (1) AU758627B2 (de)
CA (1) CA2340328C (de)
DE (1) DE69933877T2 (de)
IL (2) IL141494A0 (de)
NO (1) NO20010920L (de)
NZ (1) NZ510002A (de)
WO (1) WO2000010578A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504847A (en) * 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
AU9017901A (en) * 2000-08-07 2002-02-18 Angiogenetics Sweden Ab Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the vonhippel-lindau tumor suppressor protein
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
CA2446946A1 (en) 2001-05-09 2002-11-14 Anges Mg, Inc. Gene transfer of angiogenic factor for skin disease
AU2002302252A1 (en) * 2001-05-23 2002-12-03 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
US6838430B2 (en) * 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
DK2298301T3 (en) * 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
US7053046B2 (en) * 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN101518533A (zh) * 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN1921892A (zh) * 2003-10-17 2007-02-28 艾克蒂斯生物公司 用于治疗癌症的msp36的慢病毒载体传递
JP2007510734A (ja) * 2003-11-07 2007-04-26 ザ ヘンリー エム． ジャクソン ファウンデイション 低酸素誘導性遺伝子発現の活性化
AU2004294950A1 (en) * 2003-11-26 2005-06-16 Entelos, Inc. Treatment of rheumatoid arthritis with Hypoxia-Inducible Factor 1alpha antagonists
US7294123B2 (en) * 2003-12-17 2007-11-13 Corris Neurovascular, Inc. Activatable bioactive vascular occlusive device and method of use
US20050137568A1 (en) * 2003-12-17 2005-06-23 Jones Donald K. Activatable bioactive implantable medical device and method of use
CN1980573A (zh) * 2003-12-31 2007-06-13 艾克蒂斯生物公司 用于治疗癌症的天然和突变igfbp－3的慢病毒载体传送
US7247159B2 (en) * 2004-04-08 2007-07-24 Cordis Neurovascular, Inc. Activatable bioactive vascular occlusive device
US20060003961A1 (en) * 2004-06-18 2006-01-05 The John Hopkins University Negative regulation of hypoxia inducible factor 1 by OS-9
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
WO2006130320A2 (en) * 2005-05-11 2006-12-07 University Of Florida Research Foundation, Inc. Repair of the bone marrow vasculature
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
WO2007048004A2 (en) * 2005-10-21 2007-04-26 Cornell Research Foundation, Inc. Compounds for enhancing hypoxia inducible factor activity and methods of use
KR100949975B1 (ko) * 2006-03-30 2010-03-29 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
US7759306B2 (en) * 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
EP2051988A4 (de) 2006-07-31 2010-06-02 Vascular Biogenics Ltd Polypeptide und diese codierende polynukleotide und ihre verwendung bei der behandlung von medizinischen erkrankungen im zusammenhang mit ischämie
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
EP2066791B1 (de) 2006-10-03 2012-09-12 Genzyme Corporation Gentherapie für amyotrophe lateralsklerose und andere rückenmarkserkrankungen
KR100992526B1 (ko) * 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
EP4512819A3 (de) * 2015-08-12 2025-08-06 The General Hospital Corporation Zusammensetzungen und verfahren zur förderung der hypoxie oder der hypoxiereaktion zur behandlung und prävention von mitochondriendysfunktion und oxidativen stresserkrankungen
US12544403B2 (en) 2019-01-10 2026-02-10 The General Hospital Corporation Methods to treat mitochondrial-associated dysfunctions or diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
NZ504847A (en) 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1

Also Published As

Publication number Publication date
IL141494A0 (en) 2002-03-10
EP1107768B1 (de) 2006-11-02
EP1107768A4 (de) 2004-12-29
US6124131A (en) 2000-09-26
NO20010920L (no) 2001-04-23
WO2000010578A1 (en) 2000-03-02
EP1107768A1 (de) 2001-06-20
DE69933877D1 (de) 2006-12-14
AU758627B2 (en) 2003-03-27
CA2340328C (en) 2011-06-21
DE69933877T2 (de) 2007-06-21
CA2340328A1 (en) 2000-03-02
AU5691499A (en) 2000-03-14
IL141494A (en) 2009-05-04
US6562799B1 (en) 2003-05-13
NZ510002A (en) 2003-11-28
JP2002523028A (ja) 2002-07-30
NO20010920D0 (no) 2001-02-23
US20030176349A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
ATE344043T1 (de) Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
HU9300541D0 (en) Ligand to receptor c-kit qnd method for its utilization
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
ATE180976T1 (de) Insizierbare lecithin gel
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
DK0639979T3 (da) Ligand for c-kit-receptoren og fremgangsmåde til anvendelse heraf
DE68926679D1 (de) Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
EE9900428A (et) Köhavastased ravimkoostised
DE69030387D1 (de) Chinoloncarbonsäure-metallionsäurekomplexe
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
DE68909267D1 (de) Medikament zur Behandlung von fibrotischer Störung und antifibrotische Verbindung.
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ES2169124T3 (es) Acido 4-aminomicofenolico 6-sustituido y derivados con actividad inmunosupresora.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE206056T1 (de) Therapeutisches agens für neutropenie
SU950354A1 (ru) Способ лечени синдрома зап стного канала
ATE218869T1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
MX9604455A (es) FORMULACIaN FARMACÉUTICA PARA ADMINISTRACION SUBCUT??NEA, INTRAMUSCULAR O INTRADÉRMICA DE FACTOR VIII O FACTOR IX.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties